There’s fear the “second wave” of the coronavirus is already here.
In fact, new cases and hospitalizations are aggressively sweeping across Florida, California, Texas, Alaska, Arkansas, Kentucky, Mississippi, North Carolina, Oregon, and South Carolina.
Worse, according to former FDA chief Dr. Scott Gottlieb, coronavirus hot spots “could quickly get out of control.”
Thankfully, we may be nearing a potential vaccine.
Moderna Inc. (MRNA), for example, just advanced late-stage development of its vaccine. Better, it just finalized the Phase 3 study protocol based on feedback from US FDA.
The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S. and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Plus, Moderna has completed manufacture of vaccine required to start the Phase 3 study, and expects dosing in the Phase 3 study to begin in July.
In addition, Israel is reportedly in talks to buy Moderna’s vaccine, according to Reuters. And analysts at Piper Jaffray just reiterated a buy rating with a $100 price target.